Using Urine Tumor DNA to De-Intensify Surveillance in Non-Muscle Invasive Bladder Cancer
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorLahey Clinic
About this trial
The goal of this clinical trial is to use urine tumor DNA (utDNA) as an indicator for non-muscle invasive bladder cancer to identify patients suitable for less frequent cystoscopy surveillance.
Eligibility criteria
Qualifiers
AUA high-risk bladder cancer1
Received induction BCG or gemcitabine/docetaxel
Negative initial post-induction therapy assessment (negative cytology and cystoscopy +/- biopsy)
Disqualifiers
High-risk NMIBC within 3 years
Prior induction intravesical therapy
Variant histology
Concurrent upper tract disease
Trial design
Treatments tested in this trial
- UroAmp Test (Convergent Genomics, Inc.)
Treatment groups
56 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov